Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Consolidated Net Income (2018 - 2025)

Historic Consolidated Net Income for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$29.8 million.

  • X4 Pharmaceuticals' Consolidated Net Income rose 1875.14% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.1 million, marking a year-over-year decrease of 46742.65%. This contributed to the annual value of -$37.4 million for FY2024, which is 6298.2% up from last year.
  • As of Q3 2025, X4 Pharmaceuticals' Consolidated Net Income stood at -$29.8 million, which was up 1875.14% from -$25.7 million recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Consolidated Net Income peaked at $90.8 million during Q2 2024, and registered a low of -$55.7 million during Q2 2023.
  • In the last 5 years, X4 Pharmaceuticals' Consolidated Net Income had a median value of -$22.0 million in 2022 and averaged -$19.8 million.
  • Over the last 5 years, X4 Pharmaceuticals' Consolidated Net Income had its largest YoY gain of 26304.03% in 2024, and its largest YoY loss of 149201.74% in 2024.
  • X4 Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$30.2 million in 2021, then rose by 3.65% to -$29.1 million in 2022, then surged by 34.27% to -$19.1 million in 2023, then crashed by 108.16% to -$39.8 million in 2024, then increased by 25.13% to -$29.8 million in 2025.
  • Its Consolidated Net Income stands at -$29.8 million for Q3 2025, versus -$25.7 million for Q2 2025 and $282000.0 for Q1 2025.